Vaccine-derived poliovirus type 2 detected in Papua New Guinea children

Papua New Guinea has confirmed a polio outbreak after two healthy children in the port city of Lae tested positive for circulating vaccine-derived poliovirus type 2 (cVDPV2), WHO reported [s1]. The virus was picked up first in an environmental sample and then in stool from two of 25 children screened; it is genetically linked to an emergence that previously caused an outbreak in neighbouring Indonesia, and it has appeared in a country where routine polio immunisation sits far below the level needed to stop transmission [s1].

The country's IHR national focal point notified WHO on 9 May 2025 of the detections in Lae, Morobe province [s1]. The trail began earlier: an environmental surveillance site reported cVDPV2 on 4 April 2025, and stool samples from 25 healthy children were collected in the catchment area on 10 April as part of an in-depth investigation [s1]. On 8 May, the WHO regional reference laboratory in Australia, the Victorian Infectious Diseases Reference Laboratory, confirmed that two of those children — from two separate villages, both asymptomatic — carried poliovirus type 2 [s1].

What "vaccine-derived" means here

The label sounds alarming and is worth unpacking. Oral polio vaccine contains live, weakened virus that replicates briefly in the gut and builds immunity [s2]. In populations that are not well vaccinated, that weakened strain can keep circulating from person to person, and the longer it circulates the more it mutates; on rare occasions it reacquires the ability to paralyse, exactly as wild poliovirus does [s2]. Genetic sequencing of the Lae isolates revealed 18 to 19 nucleotide differences from the original Sabin 2 vaccine strain — the accumulated change that marks a vaccine-derived lineage rather than a fresh vaccine dose [s1]. All the isolates were closely related to one another and genetically linked to the INO-PAP-2 emergence behind an earlier Indonesian outbreak [s1].

Under the Global Polio Eradication Initiative's rules, the detection of type 2 poliovirus in this way is classified as a polio outbreak [s1]. That the two children were healthy is not reassuring: up to 90% of polio infections are asymptomatic or cause only mild illness, roughly one infection in 200 leads to irreversible paralysis, and 2–10% of those paralysed die [s1]. The incubation period runs about 7–10 days but can stretch from 4 to 35 [s1]. Because most infection is silent, a single confirmed case — or a single positive sewage sample — is read as evidence of wider unseen spread.

Why coverage is the whole story

The outbreak's significance is set by how many children are unprotected. As of 2024, national coverage for the third dose of oral polio vaccine (OPV3) in Papua New Guinea was 44% [s1]. In Morobe province, where the virus was found, coverage with bivalent oral vaccine has stayed below 40% for the past five years, ranging between 28% and 37%, while first-dose inactivated vaccine (IPV1) coverage held at 52–54% [s1]. Lae city itself is better protected — 73% for bivalent oral vaccine and 90% for IPV1 — but the surrounding province is not, and it is that low-immunity hinterland that lets a vaccine-derived strain persist and mutate [s1].

WHO judges the risk of local spread to be high given the sub-national immunity gaps, though it notes the affected province shares no international border [s1]. Lae is nonetheless a major commercial hub and a designated seaport of entry, which raises the risk of the virus being carried elsewhere [s1]. The Western Pacific Region has been free of endemic polio since 2000, and WHO reports no other ongoing poliovirus outbreaks in the region — but it repeats the standing warning that as long as any poliovirus circulates anywhere, importation can reseed an outbreak wherever population immunity is low [s1].

The response, and what it is up against

Authorities have kept national and provincial emergency operations centres activated, stepped up surveillance for acute flaccid paralysis and expanded environmental testing, and accelerated catch-up with inactivated vaccine nationwide to reduce the risk of paralysis while a targeted oral vaccine campaign is prepared with GPEI partners [s1]. Cross-border coordination and IHR reporting round out the immediate measures [s1].

The structural difficulty is that type 2 outbreaks are a predictable side-effect of eradication's own machinery. Type 2 wild poliovirus was declared eradicated and the type 2 component withdrawn from routine oral vaccine in April and May 2016; since then, mucosal immunity to type 2 has fallen in successive birth cohorts, which is why type 2 vaccine-derived viruses now account for most polio outbreaks worldwide [s1]. The international spread of poliovirus has been a Public Health Emergency of International Concern since 5 May 2014, a status most recently extended on 6 November 2024 [s1].

For Papua New Guinea the practical question is coverage. A vaccine-derived outbreak is, at root, a marker of too many unimmunised children — the same gap that leaves zero-dose children exposed elsewhere, and the reason immunisation programmes ended 2025 short of their targets. Whether this detection stays a contained event or becomes a paralytic outbreak will turn on how fast the response can lift immunity in Morobe, not on the handful of viruses found so far. It sits alongside the type 1 vaccine-derived detections reported in Israel as evidence that the last stretch of eradication is also its most fragile.

Sources

• Circulating vaccine-derived poliovirus type 2 (cVDPV2) - Papua New Guinea — World Health Organization, 20 May 2025
• Poliomyelitis (fact sheet) — World Health Organization, 24 July 2024